GlassScriptPhysician profile
Enrique Zarate
NPI 1417939851
$4,935.96
in general payments reported to CMS, 2019-2025
22 companies · $938 in 2025
The $938 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $640 · 2020: $432 · 2021: $577 · 2022: $903 · 2023: $672 · 2024: $775 · 2025: $938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,384.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,572.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,015.31 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $339.83 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $270.74 | 2021-2025 | |
| Abbvie INC. | $240.03 | 2021-2025 | |
| Amgen INC. | $211.87 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $210.72 | 2020-2025 | Jardiance, Zepbound, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.01 | 2021-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $161.29 | 2022-2023 | Seglentis, Livalo |
| Sanofi-Aventis U.S. LLC | $158.74 | 2019-2022 | |
| Amarin Pharma, INC. | $136.86 | 2019 | |
| Vanda Pharmaceuticals INC. | $130.75 | 2025 | Hetlioz, Fanapt |
| Biohaven Pharmaceutical Holding Company LTD. | $95.79 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $48.15 | 2021 | |
| Merck Sharp & Dohme LLC | $37.27 | 2020-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $35.91 | 2019-2020 | |
| Corcept Therapeutics | $24.30 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $18.52 | 2025 | Rexulti |
| Astellas Pharma US INC | $17.85 | 2025 | Veozah |
| Arbor Pharmaceuticals, INC. | $16.98 | 2019 | |
| Glaxosmithkline, LLC. | $16.43 | 2020 | |
| Medtronic Vascular, INC. | $12.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Enrique Zarate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.